Drugs / CXCR4 modified anti-BCMA CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04727008 | Sep 2022 → Dec 2025 | plasma cell myeloma | Sichuan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CXCR4 modified anti-BCMA CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04727008 ↗ |
| Modality | Cell therapy | “CAR T cell therapy” NCT04727008 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04727008 ↗ |